Cooper Companies (The) (COO) FY2025 10-K Annual Report
Cooper Companies (The) (COO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Dec 5, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Cooper Companies (The) FY2025 10-K Analysis
Business Overview
- • Core business model: global medical device company with two segments, CooperVision and CooperSurgical, focused on vision, fertility, and women’s health
- • Expanded geographic reach, selling products in over 130 countries
Management Discussion & Analysis
- • Outlook optimistic on long-term contact lens and general health care market growth
- • Risks and uncertainties acknowledged in global operating environment
Risk Factors
- • Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan
- • Macroeconomic exposure: 5% net sales growth in Americas and 8% in EMEA, driven by silicone hydrogel lenses, with revenue positively impacted by $16 million favorable foreign exchange in 2025
Cooper Companies (The) FY2025 Key Financial MetricsXBRL
Revenue
$4.1B
▲ +5.1% YoY
Net Income
$375M
▼ -4.4% YoY
Gross Margin
65.5%
▼ -110bp YoY
Operating Margin
16.7%
▼ -143bp YoY
Net Margin
9.2%
▼ -91bp YoY
ROE
4.6%
▼ -30bp YoY
Total Assets
$12.4B
▲ +0.6% YoY
EPS (Diluted)
$1.87
▼ -4.6% YoY
Operating Cash Flow
$796M
▲ +12.2% YoY
Source: XBRL data from Cooper Companies (The) FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cooper Companies (The)
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.